Abdel-Qadir H, Bobrowski D, Zhou L, Austin PC, Calvillo-Arguelles O, Amir E, Lee DS, Thavendiranathan P (2021) Statin exposure and risk of heart failure after anthracycline- or trastuzumab-based chemotherapy for early breast cancer: a propensity score-matched cohort study. J Am Heart Assoc. https://doi.org/10.1161/JAHA.119.018393

Article  PubMed  PubMed Central  Google Scholar 

Abdullah CS, Alam S, Aishwarya R, Miriyala S, Bhuiyan MAN, Panchatcharam M, Pattillo CB, Orr AW, Sadoshima J, Hill JA, Bhuiyan MS (2019) Doxorubicin-induced cardiomyopathy associated with inhibition of autophagic degradation process and defects in mitochondrial respiration. Sci Rep 9:2002

Article  PubMed  PubMed Central  Google Scholar 

Ahmad N, Ullah A, Chu P, Tian W, Tang Z, Sun Z (2022) Doxorubicin induced cardio toxicity through sirtuins mediated mitochondrial disruption. Chem Biol Interact. https://doi.org/10.1016/j.cbi.2022.110028

Article  PubMed  Google Scholar 

Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, Berk V, Karaca H, Kalay N, Oguzhan A, Ergin A (2015) Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail 17:81–89. https://doi.org/10.1002/ejhf.196

Article  CAS  PubMed  Google Scholar 

Alhowail AH (2023) Pioglitazone ameliorates doxorubicin-induced hypothyroidism and cardiotoxicity in rat models. Eur Rev Med Pharmacol Sci 27:9388–9395. https://doi.org/10.26355/eurrev_202310_33966

Article  CAS  PubMed  Google Scholar 

Aratani Y (2018) Myeloperoxidase: Its role for host defense, inflammation, and neutrophil function. Arch Biochem Biophys 640:47–52. https://doi.org/10.1016/j.abb.2018.01.004

Article  CAS  PubMed  Google Scholar 

Avila MS, Ayub-Ferreira SM, de Barros Wanderley MR, Das Dores Cruz F, Goncalves Brandao SM, Rigaud VOC, Higuchi-Dos-Santos MH, Hajjar LA, Kalil Filho R, Hoff PM, Sahade M, Ferrari MSM, de Paula Costa RL, Mano MS, Bittencourt Viana Cruz CB, Abduch MC, Lofrano Alves MS, Guimaraes GV, Issa VS, Bittencourt MS, Bocchi EA (2018) Carvedilol for prevention of chemotherapy-related cardiotoxicity: the CECCY trial. J Am Coll Cardiol 71:2281–2290. https://doi.org/10.1016/j.jacc.2018.02.049

Article  CAS  PubMed  Google Scholar 

Bartlett JJ, Trivedi PC, Yeung P, Kienesberger PC, Pulinilkunnil T (2016) Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy. Biochem J 473:3769–3789. https://doi.org/10.1042/BCJ20160385

Article  CAS  PubMed  Google Scholar 

Becker MMC, Arruda GFA, Berenguer DRF, Buril RO, Cardinale D, Brandao SCS (2023) Anthracycline cardiotoxicity: current methods of diagnosis and possible role of (18)F-FDG PET/CT as a new biomarker. Cardiooncology 9:17. https://doi.org/10.1186/s40959-023-00161-6

Article  PubMed  PubMed Central  Google Scholar 

Bell RM, Basalay M, Botker HE, Beikoghli Kalkhoran S, Carr RD, Cunningham J, Davidson SM, England TJ, Giesz S, Ghosh AK, Golforoush P, Gourine AV, Hausenloy DJ, Heusch G, Ibanez B, Kleinbongard P, Lecour S, Lukhna K, Ntsekhe M, Ovize M, Salama AD, Vilahur G, Walker JM, Yellon DM (2022) Remote ischaemic conditioning: defining critical criteria for success-report from the 11th Hatter Cardiovascular Workshop. Basic Res Cardiol 117:39. https://doi.org/10.1007/s00395-022-00947-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bhagat A, Shrestha P, Jeyabal P, Peng Z, Watowich SS, Kleinerman ES (2022) Doxorubicin-induced cardiotoxicity is mediated by neutrophils through release of neutrophil elastase. Front Oncol. https://doi.org/10.3389/fonc.2022.947604

Article  PubMed  PubMed Central  Google Scholar 

Bikomeye JC, Terwoord JD, Santos JH, Beyer AM (2022) Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. Am J Physiol Heart Circ Physiol 323:H702–H720. https://doi.org/10.1152/ajpheart.00231.2022

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bosch X, Rovira M, Sitges M, Domenech A, Ortiz-Perez JT, de Caralt TM, Morales-Ruiz M, Perea RJ, Monzo M, Esteve J (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61:2355–2362. https://doi.org/10.1016/j.jacc.2013.02.072

Article  CAS  PubMed  Google Scholar 

Botker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deshwal S, Devaux Y, Di Lisa F, Di Sante M, Efentakis P, Femmino S, Garcia-Dorado D, Giricz Z, Ibanez B, Iliodromitis E, Kaludercic N, Kleinbongard P, Neuhauser M, Ovize M, Pagliaro P, Rahbek-Schmidt M, Ruiz-Meana M, Schluter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinandy P, Heusch G (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113:39. https://doi.org/10.1007/s00395-018-0696-8

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cadeddu C, Piras A, Mantovani G, Deidda M, Dessi M, Madeddu C, Massa E, Mercuro G (2010) Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J 160(487):e481-487. https://doi.org/10.1016/j.ahj.2010.05.037

Article  CAS  Google Scholar 

Cardinale D, Ciceri F, Latini R, Franzosi MG, Sandri MT, Civelli M, Cucchi G, Menatti E, Mangiavacchi M, Cavina R, Barbieri E, Gori S, Colombo A, Curigliano G, Salvatici M, Rizzo A, Ghisoni F, Bianchi A, Falci C, Aquilina M, Rocca A, Monopoli A, Milandri C, Rossetti G, Bregni M, Sicuro M, Malossi A, Nassiacos D, Verusio C, Giordano M, Staszewsky L, Barlera S, Nicolis EB, Magnoli M, Masson S, Cipolla CM, Investigators I-OS (2018) Anthracycline-induced cardiotoxicity: a multicenter randomised trial comparing two strategies for guiding prevention with enalapril: the International CardioOncology Society-one trial. Eur J Cancer 94:126–137. https://doi.org/10.1016/j.ejca.2018.02.005

Article  CAS  PubMed  Google Scholar 

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, Civelli M, Lamantia G, Colombo N, Curigliano G, Fiorentini C, Cipolla CM (2015) Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation 131:1981–1988. https://doi.org/10.1161/CIRCULATIONAHA.114.013777

Article  CAS  PubMed  Google Scholar 

Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, Martinelli G, Veglia F, Fiorentini C, Cipolla CM (2006) Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation 114:2474–2481. https://doi.org/10.1161/CIRCULATIONAHA.106.635144

Article  CAS  PubMed  Google Scholar 

Cheung YF, Li VW, So EK, Cheng FW, Yau JP, Chiu SY, Wong WH, Cheuk DK (2023) Remote ischemic conditioning in pediatric cancer patients receiving anthracycline chemotherapy: a sham-controlled single-blind randomized trial. JACC CardioOncol 5:332–342. https://doi.org/10.1016/j.jaccao.2022.11.020

Article  PubMed  PubMed Central  Google Scholar 

Chung WP, Yang HL, Hsu YT, Hung CH, Liu PY, Liu YW, Chan SH, Tsai KL (2022) Real-time exercise reduces impaired cardiac function in breast cancer patients undergoing chemotherapy: a randomized controlled trial. Ann Phys Rehabil Med. https://doi.org/10.1016/j.rehab.2021.101485

Article  PubMed  Google Scholar 

de Baat EC, Mulder RL, Armenian S, Feijen EA, Grotenhuis H, Hudson MM, Mavinkurve-Groothuis AM, Kremer LC, van Dalen EC (2022) Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD014638.pub2

Article  PubMed  PubMed Central  Google Scholar 

Diaz-Guerra A, Villena-Gutierrez R, Clemente-Moragon A, Gomez M, Oliver E, Fernandez-Tocino M, Galan-Arriola C, Cadiz L, Ibanez B (2024) Anthracycline cardiotoxicity induces progressive changes in myocardial metabolism and mitochondrial quality control: novel therapeutic target. JACC CardioOncol 6:217–232. https://doi.org/10.1016/j.jaccao.2024.02.005

Article  PubMed  PubMed Central  Google Scholar 

Efentakis P, Choustoulaki A, Kwiatkowski G, Varela A, Kostopoulos IV, Tsekenis G, Ntanasis-Stathopoulos I, Georgoulis A, Vorgias CE, Gakiopoulou H, Briasoulis A, Davos CH, Kostomitsopoulos N, Tsitsilonis O, Dimopoulos MA, Terpos E, Chlopicki S, Gavriatopoulou M, Andreadou I (2024) Early microvascular coronary endothelial dysfunction precedes pembrolizumab-induced cardiotoxicity. Preventive role of high dose of atorvastatin. Basic Res Cardiol. https://doi.org/10.1007/s00395-024-01046-0

Article  PubMed  Google Scholar 

Ferreira A, Cunha-Oliveira T, Simoes RF, Carvalho FS, Burgeiro A, Nordgren K, Wallace KB, Oliveira PJ (2017) Altered mitochondrial epigenetics associated with subchronic doxorubicin cardiotoxicity. Toxicology 390:63–73. https://doi.org/10.1016/j.tox.2017.08.011

Article  CAS  PubMed  Google Scholar